Dr. Manish Bais is a Research Assistant Professor in the Department of Molecular and Cell Biology at Boston University’s Henry M. Goldman School of Dental Medicine. Dr. Bais is also an important member of the Oral Cancer Research Initiative (OCRI). With funding from the OCRI, Dr. Bais travelled to the National Institute of Dental and Craniofacial Research in the summer of 2013 to receive mouse model training in the lab of Dr. Roberto Weigert. Dr. Bais has made large contributions to the initiative with the development of an orthotropic oral cancer mouse model.
The orthotropic nude mouse models of non-metastatic and metastatic tongue cancer that Dr. Bais has developed will facilitate mechanistic in vivo studies and preclinical testing of novel targets for anti-oral cancer therapy. Specifically, he has generated mice with non-metastatic tongue tumors following injection of human tongue squamous cell carcinoma (OSCC) CAL27 cells into tongues of nude mice. In addition, Dr. Bais has generated mice with tongue tumors formed by injection of SCC2 cells that metastasize to lung, bone and liver, sites of metastases of human tongue cancers.
Dr. Bais is collaborating with many OCRI investigators including Dr. Maria Kukuruzinska, Dr. Philip Trackman, Dr. Bob Varelas and Dr. David Sherr. This animal model and other models still in progress can help us to better understand the biology of oral cancer as well as provide new therapeutic opportunities in the treatment of this deadly disease.
Boston University Henry M. Goldman School of Dental Medicine
Translational Dental Medicine
BU-BMC Cancer Center
Evans Center for Interdisciplinary Biomedical Research
Genome Science Institute
2015-2017 RO3- NIH/ NIDCR:
LOXL2 in TMJ osteoarthritis
2015-2016 Henry M. Goldman School of Dental Medicine:
Lysine specific demethylase 1 inhibitor for improved personalized oral cancer therapy
2014-2015 CNN Pilot grant, Center for Nanoscience and Nanotechnology (CNN), Boston University:
Nanodelivery Approaches for Targeting DPAGT1 and LSD1 for oral Squamous Cell Carcinoma therapy
2014-2015 CTSI, BUSDM:
Patient-derived Tumors Orthotopic Oral Cancer Mouse Models
2012-2013 BUSDM seed funding:
LOXL2 in Anabolic Response to TMJ-Osteoarthritis
Epigenetic Targeting of LSD1 OSCC for Therapy
09/01/2018 - 08/31/2021 (PI)NIH/National Institute of Dental & Craniofacial Research5R21DE026892-02
LOXL2 in Temporomandibular Joint Osteoarthritis
08/01/2015 - 07/31/2018 (PI)NIH/National Institute of Dental & Craniofacial Research5R03DE025274-02
Publications listed below are automatically derived from MEDLINE/PubMed and other
sources, which might result in incorrect or missing publications. Faculty can
to make corrections and additions.
Showing 10 of 33 results.
Tashkandi MM, Alsaqer SF, Alhousami T, Ali F, Wu YC, Shin J, Mehra P, Wolford LM, Gerstenfeld LC, Goldring MB, Bais MV. LOXL2 promotes aggrecan and gender-specific anabolic differences to TMJ cartilage. Sci Rep. 2020 11 19; 10(1):20179.View Related Profiles. PMID: 33214607
Chandler KB, Alamoud KA, Stahl VL, Nguyen BC, Kartha VK, Bais MV, Nomoto K, Owa T, Monti S, Kukuruzinska MA, Costello CE. ß-Catenin/CBP inhibition alters epidermal growth factor receptor fucosylation status in oral squamous cell carcinoma. Mol Omics. 2020 06 01; 16(3):195-209.View Related Profiles. PMID: 32203567
Tashkandi M, Ali F, Alsaqer S, Alhousami T, Cano A, Martin A, Salvador F, Portillo F, C Gerstenfeld L, Goldring MB, Bais MV. Lysyl Oxidase-Like 2 Protects against Progressive and Aging Related Knee Joint Osteoarthritis in Mice. Int J Mol Sci. 2019 Sep 27; 20(19). PMID: 31569601
Bais MV. Impact of Epigenetic Regulation on Head and Neck Squamous Cell Carcinoma. J Dent Res. 2019 03; 98(3):268-276. PMID: 30615537
Kartha VK, Alamoud KA, Sadykov K, Nguyen BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, Snyder-Cappione JE, Belkina AC, Bais MV, Monti S, Kukuruzinska MA. Functional and genomic analyses reveal therapeutic potential of targeting ß-catenin/CBP activity in head and neck cancer. Genome Med. 2018 07 20; 10(1):54.View Related Profiles. PMID: 30029671
Bais MV. Targeting oral cancer epigenome via LSD1. Aging (Albany NY). 2017 12 11; 9(12):2455-2456. PMID: 29232656
Trackman PC, Bais MV. Measurement of lysyl oxidase activity from small tissue samples and cell cultures. Methods Cell Biol. 2018; 143:147-156.View Related Profiles. PMID: 29310775
Bais MV, Goldring MB. LOXL2 as a protective in osteoarthritis cartilage. Aging (Albany NY). 2017 Oct 27; 9(10):2024-2025. PMID: 29080554
Alshenibr W, Tashkandi MM, Alsaqer SF, Alkheriji Y, Wise A, Fulzele S, Mehra P, Goldring MB, Gerstenfeld LC, Bais MV. Anabolic role of lysyl oxidase like-2 in cartilage of knee and temporomandibular joints with osteoarthritis. Arthritis Res Ther. 2017 Aug 02; 19(1):179.View Related Profiles. PMID: 28764769
Alsaqer SF, Tashkandi MM, Kartha VK, Yang YT, Alkheriji Y, Salama A, Varelas X, Kukuruzinska M, Monti S, Bais MV. Inhibition of LSD1 epigenetically attenuates oral cancer growth and metastasis. Oncotarget. 2017 Sep 26; 8(43):73372-73386.View Related Profiles. PMID: 29088714
This graph shows the total number of publications by year, by first, middle/unknown,
or last author.